

Table 1. Study characteristics

First author, year	Country	Study design	Study population and study period	Total Sample size	Exposed	Unexposed	Comparator group	Association
Imbroane, 2025	USA	Retrospective cohort study	Pregnant, $\geq$ 18 years, 1 January 2020 – 13 June 2024	8,534	4,267	4,267 matched unexposed)	Pregnant with no previous history of GLP-1 RA use. The cohort was matched 1:1, for age, race, ethnicity, and comorbidities.	–
Maya, 2025	USA	Retrospective cohort study	Singleton pregnancies, June 2016 - March 2025	1,728*	432	1,296	Unexposed pregnancies matched 1:3 via propensity score (no GLP-1 RAs from 3 years before to 90 days after conception)	+
Pondugula, 2025	USA	Retrospective cohort study	Patients with a delivery admission (2014–2024) and GLP-1 RA exposure up to 1 year before pregnancy	618	243	375	Two groups: 1) Pregestational diabetes (managed with non-GLP-1 RA meds); 2) Weight-management (BMI $\geq$ age 30)	–

* we considered only the HDP population without the pregestational HDP.

* “+” indicates increased HDP risk associated with GLP-1 RA exposure; “–” indicates reduced HDP risk.